ClinicalTrials.gg
Not yet recruitingNCT07860515SYSLE-1Updated Oct 8, 2026

Effect of Systematic and Sequential Leg Elevation on Cardiac Output in Healthy Volunteers

An interventional study of Passive Leg Raising and Non-Invasive Ventilation in Healthy Adult, Cardiac Output and Hemodynamic, sponsored by Centre Hospitalier Régional d'Orléans. Not yet recruiting at 1 site in France. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by Centre Hospitalier Régional d'Orléans · Not applicable, Interventional, and Basic science

How we know

Updated Oct 6, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Passive leg raising (PLR) transiently increases venous return and cardiac preload and is commonly used to predict fluid responsiveness in critically ill patients. Repeated fluid boluses contribute to fluid overload in septic shock, whereas PLR may provide similar hemodynamic effects without fluid administration.

Before evaluating repeated PLR in septic shock patients, it is necessary to determine whether the cardiac output response to PLR remains present during repeated PLR maneuvers.

SYSLE-1 is a prospective interventional physiological crossover study conducted in healthy volunteers. Participants will undergo six consecutive passive leg raising sessions performed either during spontaneous breathing or non-invasive ventilation, in randomized order. The study aims to determine whether the increase in cardiac output induced by the first PLR maneuver persists during repeated PLR sessions.

Read the detailed description

The passive leg raising maneuver induces a reversible transfer of venous blood from the lower extremities toward the thoracic compartment, thereby increasing cardiac preload. In preload-dependent individuals, PLR increases stroke volume and cardiac output without administration of intravenous fluids.

In septic shock, repeated fluid challenges remain common during the first days of management but may contribute to positive fluid balance, tissue edema, organ dysfunction, and increased mortality. Since the hemodynamic effects of PLR resemble those of a fluid challenge while avoiding fluid administration, repeated PLR maneuvers could represent an alternative strategy for improving preload and cardiac output.

The SYSLE-1 study is designed as the first phase of a broader research program aimed at evaluating repeated PLR in septic shock patients. The present study investigates whether the cardiac output response to PLR remains preserved during six repeated PLR sessions in healthy volunteers.

Participants will complete two study days in randomized order: one under spontaneous breathing and one under non-invasive ventilation. During each study day, six PLR sessions lasting 10 minutes each will be performed and separated by 50-minute recovery periods in a semi-recumbent position.

Cardiac output measured by thoracic bioreactance is the primary endpoint. Additional physiological measurements include arterial pressure, heart rate variability, brachial artery diameter, cardiac output measured using pulse contour analysis and echocardiography, end-tidal carbon dioxide, comfort assessments, and safety outcomes.

02

Conditions studied

  • Healthy Adult
  • Cardiac Output
  • Hemodynamic
  • Passive Leg Raising

Keywords

  • Passive leg raising
  • Cardiac Ouptut
  • Thoracic Bioreactance
  • Noninvasive Ventilation
03

In context

Lead sponsor

Centre Hospitalier Régional d'Orléans is the lead sponsor of 132 studies on the registry; 32 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female participant.
  • Age 18 years or older.
  • Healthy volunteer without known acute or chronic disease.
  • No significant cardiovascular or respiratory disease.
  • No medication use within 10 days before the first study day (except oral ).
  • Intact upper and lower limbs.
  • Written .

Exclusion criteria

Exclusion Criteria:

  • greater than 35 kg/m².
  • Use of illicit psychoactive substances within the previous 3 months.
  • Congenital or acquired absence of part or all of an upper or lower limb.
  • Known allergy to hydrocolloid dressings.
  • Pregnant or breastfeeding women.
  • Under guardianship, curatorship, or legal protection.
  • Deprived of liberty.
  • Not affiliated with a health insurance system.
  • Participation in another drug study during an exclusion period.
  • Member of the Lieu de Recherches Interventionnelles sur la Personne Humaine (LRIPH) or Intensive Care Unit staff.
  • Refusal to participate.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Spontaneous Breathing

    Participants undergo one study day during spontaneous breathing in room air. Each study day consists of six repeated passive leg raising (PLR) sessions performed once every hour over approximately six hours. Before each PLR session, participants remain in a semi-recumbent position (30° trunk elevation) for 5 minutes. They are then moved to a passive leg raising position with the trunk horizontal and legs elevated to 45° for 10 minutes using an electrically operated bed. Following each PLR maneuver, participants return to the semi-recumbent position for 50 minutes before the next PLR session. Throughout the study day, continuous or repeated measurements of cardiac output, arterial pressure, heart rate, respiratory rate, oxygen saturation, heart rate variability, echocardiographic parameters, and brachial artery diameter are performed according to the study schedule.

    Procedure: Passive Leg Raising · Procedure: Non-Invasive Ventilation

  • Experimental
    Non-Invasive Ventilation

    Participants undergo one study day during non-invasive ventilation (NIV) delivered through an oronasal mask. Each study day consists of 6 repeated passive leg raising (PLR) sessions performed once every hour over approximately 6 hours. Before each PLR session, NIV is applied for 5 minutes while the participant remains in a semi-recumbent position (30° trunk elevation). Participants are then moved to a passive leg raising position with the trunk horizontal and legs elevated to 45° for 10 minutes while NIV is maintained. NIV is continued for an additional 5 minutes after return to the semi-recumbent position and is reapplied during the last 5 minutes preceding the next PLR session. This results in repeated 20-minute NIV exposure periods surrounding each PLR maneuver. Continuous or repeated measurements of cardiac output, arterial pressure, heart rate, respiratory rate, oxygen saturation, end-tidal carbon dioxide, heart (etc.) are performed according to the study schedule.

    Procedure: Passive Leg Raising · Procedure: Non-Invasive Ventilation

Interventions

  • ProcedurePassive Leg Raising

    Passive leg raising is performed using an electrically operated hospital bed to move participants from a semi-recumbent position (30° trunk elevation) to a position with the trunk horizontal and legs elevated at 45°. Each maneuver lasts 10 minutes and is repeated six times at hourly intervals.

  • ProcedureNon-Invasive Ventilation

    Non-invasive ventilation is delivered via an oronasal mask using a critical care ventilator. NIV is applied for 5 minutes before passive leg raising, throughout the 10-minute maneuver, and for 5 minutes after return to the semi-recumbent position, resulting in six repeated 20-minute NIV periods during the study day. Ventilator settings: FiO2 21%, initial PEEP 5 cmH2O (adjustable down to 2 cmH2O for tolerance), and pressure support 0-5 cmH2O, titrated to avoid a tidal volume \>15 mL/kg predicted body weight (target 8-12 mL/kg).

06

What researchers measure

Primary outcomes

  1. Change in cardiac output during the sixth passive leg raising session compared with the first passive leg raising session, for each day of study procedure

    Cardiac output measured every minute using thoracic bioreactance. The study will assess whether the increase in cardiac output during the sixth PLR session is non-inferior to 30% of the increase observed during the first PLR session.

    Time frame: During study procedures on Days 1 and 2 (up to 10 days apart). From enrollment to the end of study (day 2) at 3 months maximum.

Secondary outcomes

  1. Change in cardiac output response across PLR sessions 1 to 6.

    Change in cardiac output measured by thoracic bioreactance during each passive leg raising session. Cardiac output changes observed during sessions 1 through 6 will be described and compared.

    Time frame: During each study day, across six passive leg raising sessions performed over approximately 6 hours. From enrollment to the end of study (day 2) at 3 months maximum.

  2. Effect of ventilation mode on cardiac output response to passive leg raising

    Comparison of the increase in cardiac output induced by passive leg raising between spontaneous breathing sessions and non-invasive ventilation sessions using thoracic bioreactance measurements.

    Time frame: During the two study days (up to 10 days apart). From enrollment to the end of study (day 2) at 3 months maximum.

  3. Cardiac output evolution during passive leg raising

    Minute-by-minute cardiac output measured by thoracic bioreactance during passive leg raising to characterize the temporal profile of the hemodynamic response.

    Time frame: During each 10-minute passive leg raising session. From enrollment to the end of study (day 2) at 3 months maximum

  4. Effect of ventilation mode on cardiac output evolution during passive leg raising

    Comparison of cardiac output trajectories measured during passive leg raising under spontaneous breathing and non-invasive ventilation.

    Time frame: During each 10-minute passive leg raising session on both study days. From enrollment to the end of study (day 2) at 3 months maximum.

  5. Cardiac output recovery after passive leg raising

    Evolution of cardiac output after returning from passive leg raising to the semi-recumbent position, assessed using thoracic bioreactance.

    Time frame: During the 50-minute recovery period following each passive leg raising session. From enrollment to the end of study (day 2) at 3 months maximum.

  6. LF/HF ratio derived from heart rate variability.

    Changes in the low-frequency to high-frequency (LF/HF) ratio derived from heart rate variability analysis as an indicator of autonomic nervous system activity during repeated passive leg raising sessions

    Time frame: During each study day, across six passive leg raising sessions (approximately 6 hours). From enrollment to the end of study (day 2) at 3 months maximum.

  7. Change in brachial artery diameter measured by ultrasound.

    Brachial artery diameter assessed by ultrasound to characterize vasomotor responses associated with passive leg raising.

    Time frame: Measured before, during, and near the end of each passive leg raising session during both study days. From enrollment to the end of study (day 2) at 3 months maximum.

  8. Agreement between cardiac output measurement methods (bioreactance, Clearsight®, echocardiography).

    Comparison of cardiac output measurements obtained by thoracic bioreactance, pulse contour analysis (Clearsight®), and transthoracic echocardiography.

    Time frame: During each study day, across all passive leg raising sessions. From enrollment to the end of study (day 2) at 3 months maximum.

  9. Agreement between blood pressure measurement methods (oscillometry and Clearsight®).

    Comparison of systolic, diastolic, and mean arterial pressure measurements obtained by automated oscillometry and the Clearsight® system

    Time frame: During each study day, across all passive leg raising sessions. From enrollment to the end of study (day 2) at 3 months maximum.

  10. Correlation between end-tidal carbon dioxide and cardiac output during non-invasive ventilation

    Correlation between minute-by-minute end-tidal carbon dioxide values and cardiac output measured by thoracic bioreactance during passive leg raising sessions performed under non-invasive ventilation

    Time frame: During the non-invasive ventilation study day (approximately 6 hours). From enrollment to the end of study (day 2) at 3 months maximum.

  11. Participant-reported discomfort,.

    Participant ratings of discomfort using an 11-point numerical rating scale during study procedures and non-invasive ventilation exposure.

    Time frame: Assessed during and after each passive leg raising session on both study days (approximately 6 hours / study day). From enrollment to the end of study (day 2) at 3 months maximum. Scale from 0 to 10: 0 no discomfort and 10 worst imaginable discomfort.

  12. Participant-reported respiratory difficulty.

    Participant ratings of breathing difficulty using an 11-point numerical rating scale during study procedures and non-invasive ventilation exposure.

    Time frame: Assessed during and after each passive leg raising session on both study days (approximately 6 hours per study day). From enrollment to the end of study (day 2) at 3 months maximum. Scale from 0 to 10: 0 no difficulty and 10 worst imaginable difficulty.

  13. Participant-reported pain.

    Participant ratings of pain using an 11-point numerical rating scale during study procedures and non-invasive ventilation exposure.

    Time frame: Assessed during and after each passive leg raising session on both study days (approximately 6 hours per study day). From enrollment to the end of study (day 2) at 3 months maximum. Scale from 0 to 10: 0 no pain and 10 worst imaginable pain.

07

Study locations

1 site
08

References and documents

Publications

  • Cavallaro F, Sandroni C, Marano C, La Torre G, Mannocci A, De Waure C, Bello G, Maviglia R, Antonelli M. Diagnostic accuracy of passive leg raising for prediction of fluid responsiveness in adults: systematic review and meta-analysis of clinical studies. Intensive Care Med. 2010 Sep;36(9):1475-83. doi: 10.1007/s00134-010-1929-y. Epub 2010 May 26. PubMed 20502865 ↗
  • Carrara M, Ferrario M, Bollen Pinto B, Herpain A. The autonomic nervous system in septic shock and its role as a future therapeutic target: a narrative review. Ann Intensive Care. 2021 May 17;11(1):80. doi: 10.1186/s13613-021-00869-7. PubMed 33999297 ↗
  • Boyd JH, Forbes J, Nakada TA, Walley KR, Russell JA. Fluid resuscitation in septic shock: a positive fluid balance and elevated central venous pressure are associated with increased mortality. Crit Care Med. 2011 Feb;39(2):259-65. doi: 10.1097/CCM.0b013e3181feeb15. PubMed 20975548 ↗
  • Boulain T, Boisrame-Helms J, Ehrmann S, Lascarrou JB, Bougle A, Chiche A, Lakhal K, Gaudry S, Perbet S, Desachy A, Cabasson S, Geneau I, Courouble P, Clavieras N, Massanet PL, Bellec F, Falquet Y, Reminiac F, Vignon P, Dequin PF, Meziani F. Volume expansion in the first 4 days of shock: a prospective multicentre study in 19 French intensive care units. Intensive Care Med. 2015 Feb;41(2):248-56. doi: 10.1007/s00134-014-3576-1. Epub 2014 Dec 2. PubMed 25447804 ↗
  • Boulain T, Achard JM, Teboul JL, Richard C, Perrotin D, Ginies G. Changes in BP induced by passive leg raising predict response to fluid loading in critically ill patients. Chest. 2002 Apr;121(4):1245-52. doi: 10.1378/chest.121.4.1245. PubMed 11948060 ↗
  • Aya HD, Ster IC, Fletcher N, Grounds RM, Rhodes A, Cecconi M. Pharmacodynamic Analysis of a Fluid Challenge. Crit Care Med. 2016 May;44(5):880-91. doi: 10.1097/CCM.0000000000001517. PubMed 26683506 ↗
  • Angus DC, van der Poll T. Severe sepsis and septic shock. N Engl J Med. 2013 Aug 29;369(9):840-51. doi: 10.1056/NEJMra1208623. No abstract available. PubMed 23984731 ↗
  • Amekran Y, Damoun N, El Hangouche AJ. A focus on the assessment of the autonomic function using heart rate variability. Glob Cardiol Sci Pract. 2025 Feb 28;2025(1):e202512. doi: 10.21542/gcsp.2025.12. eCollection 2025 Feb 28. PubMed 40390990 ↗
09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2026; primary completion for Jan 2029, 27 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 3, 2026
First posted
Oct 6, 2026
StartEst.
Oct 10, 2026
Primary completionEst.
Jan 10, 2029
CompletionEst.
Jan 10, 2029
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Secondary outcomes
3 time frame changed
What changed in the outcomes
  • Time frameParticipant-reported discomfort,.Assessed during and after each passive leg raising session on both study days (approximately 6 hours per study day). From enrollment to the end of study (day 2) at 3 months maximum. → Assessed during and after each passive leg raising session on both study days (approximately 6 hours / study day). From enrollment to the end of study (day 2) at 3 months maximum. Scale from 0 to 10: 0 no discomfort and 10 worst imaginable discomfort.
  • Time frameParticipant-reported respiratory difficulty.Assessed during and after each passive leg raising session on both study days (approximately 6 hours per study day). From enrollment to the end of study (day 2) at 3 months maximum. → Assessed during and after each passive leg raising session on both study days (approximately 6 hours per study day). From enrollment to the end of study (day 2) at 3 months maximum. Scale from 0 to 10: 0 no difficulty and 10 worst imaginable difficulty.
  • Time frameParticipant-reported pain.Assessed during and after each passive leg raising session on both study days (approximately 6 hours per study day). From enrollment to the end of study (day 2) at 3 months maximum. → Assessed during and after each passive leg raising session on both study days (approximately 6 hours per study day). From enrollment to the end of study (day 2) at 3 months maximum. Scale from 0 to 10: 0 no pain and 10 worst imaginable pain.
Oct 8, 2026
Registered
First appeared on the registry
Oct 6, 2026
Show all 2 updates
  1. Oct 8, 2026
    Secondary outcomes 3 time frame changed
    What changed in the outcomes
    • Time frameParticipant-reported discomfort,.Assessed during and after each passive leg raising session on both study days (approximately 6 hours per study day). From enrollment to the end of study (day 2) at 3 months maximum. → Assessed during and after each passive leg raising session on both study days (approximately 6 hours / study day). From enrollment to the end of study (day 2) at 3 months maximum. Scale from 0 to 10: 0 no discomfort and 10 worst imaginable discomfort.
    • Time frameParticipant-reported respiratory difficulty.Assessed during and after each passive leg raising session on both study days (approximately 6 hours per study day). From enrollment to the end of study (day 2) at 3 months maximum. → Assessed during and after each passive leg raising session on both study days (approximately 6 hours per study day). From enrollment to the end of study (day 2) at 3 months maximum. Scale from 0 to 10: 0 no difficulty and 10 worst imaginable difficulty.
    • Time frameParticipant-reported pain.Assessed during and after each passive leg raising session on both study days (approximately 6 hours per study day). From enrollment to the end of study (day 2) at 3 months maximum. → Assessed during and after each passive leg raising session on both study days (approximately 6 hours per study day). From enrollment to the end of study (day 2) at 3 months maximum. Scale from 0 to 10: 0 no pain and 10 worst imaginable pain.
    + 1 other change: verification date
  2. Oct 6, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07860515
Responsible party
Sponsor
First posted
Oct 6, 2026
Start date
Oct 10, 2026 (estimated)
Primary completion
Jan 10, 2029 (estimated)
Completion
Jan 10, 2029 (estimated)
Last update
Oct 8, 2026

Study contacts

Mai-Anh PhD NAY, Physician
Contact
mai-anh.nay@chu-orleans.fr
02.38.22.95.57 ext. +33
Fanny LOUAT
Contact
fanny.louat@chu-orleans.fr
0238744295 ext. +33
Mai-Anh PhD NAY, Physician
principal investigator · Centre Hospitalier Régional d'Orléans

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion